Success Stories: Chinese Postdoctoral Researcher Secures NIW Approval After RFE for Groundbreaking Cancer Genomics Research
Client’s Testimonial:
“Thank you for your detailed response and guidance.”
On August 21st, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Filing: Postdoctoral Researcher
Country of Origin: China
State of Residence at the Time of Filing: California
Approval Notice Date: August 21st, 2025
Processing Time: 1 year, 8 months, 7 days
Case Summary:
We are pleased to share the success story of an EB-2 NIW (National Interest Waiver) approval. This approval was granted to a postdoctoral researcher from China whose research is helping advance bioinformatics-driven cancer treatment. At the time of filing, the client was employed in the United States and had already made important contributions to the field of biomedical science, particularly through her work on cancer genomics, transcription regulation, and multi-omics data analysis.
Research with Substantial Merit and National Importance
The client’s proposed endeavor focuses on building bioinformatics tools to uncover mechanisms driving cancer development and progression. Her work aims to improve therapeutic strategies and inform precision medicine approaches. This research holds national relevance, addressing the urgent need to reduce the burden of cancer and enhance drug discovery efforts.
By integrating single-cell analysis, transcriptomics, and machine learning, her work supports progress in both the healthcare and biotechnology sectors. It also aligns with the U.S. government’s strategic priorities in cancer research and advanced data technologies.
Well Positioned to Advance the Proposed Endeavor
The client holds a Ph.D. in oncology and has developed a strong academic record in cancer genomics and bioinformatics. She has authored 15 peer-reviewed journal articles, including one first-authored and four co-first-authored publications, as well as two abstracts. Her research has been cited over 540 times and published in top journals such as Nature Communications, Molecular Cell, Science Advances, and Gastroenterology. At least nine of her articles rank among the most highly cited in the field of Molecular Biology and Genetics for their publication years.
Her influence is also reflected in peer recognition. She has completed over 20 formal peer reviews for respected scientific journals, affirming her status as an expert evaluator in her discipline. In addition, her work has been supported by national research programs and cited by independent researchers in cancer genetics, tumor immunology, and transcriptional regulation.
NIW Approval and Outlook
The I-140 NIW petition was filed on December 14, 2023. An RFE was issued on April 28, 2025, and the case was approved on August 21, 2025. The RFE response was supported by strong evidence of scholarly achievement, publication impact, citation percentiles, and national relevance.
With NAILG’s support, the client successfully obtained NIW approval and is now well-positioned to continue her research in the United States. Her ongoing contributions to cancer genomics and biomedical data science promise to accelerate breakthroughs in cancer diagnostics and therapies that will benefit public health and national innovation.